Farxiga

This page shows the latest Farxiga news and features for those working in and with pharma, biotech and healthcare.

AZ expects return to growth this year after 2017 decline

The contribution of these drugs as well as blockbuster sales for antiplatelet therapy Brilinta (ticagrelor) and diabetes drug Farxiga (dapagliflozin) allowed AZ to boost operating profit by 2% to $6.86bn

Latest news

FDA’s year-end approvals take annual tally to 46

and AstraZeneca’s Farxiga (dapagliflozin) which is a big player in Europe.
J&J seeks US OK to add CV claim to Invokana label

AstraZeneca and Pfizer/Merck &Co are the laggards in the category, with AZ not expecting prospective cardiovascular outcomes data for Farxiga (dapagliflozin) until 2019 and Pfizer and Merck still waiting for
AZ data suggest SGLT2 inhibitors can reduce heart failure risk

AZ data suggest SGLT2 inhibitors can reduce heart failure risk. Publishes real-world data for study involving Forxiga/Farxiga, Invokana and Jardiance. ... In the meantime, AZ is conducting its own large-scale clinical trials to determine the effect of
Merck & Co and Pfizer take aim at diabetes with trio of new drugs

The first SGLT2 inhibitor to be approved in the US was Johnson &Johnson's Invokana (canagliflozin) in 2013, while in Europe it was AstraZeneca's Forxiga/Farxiga (dapagliflozin) the previous year.
AZ gets US approval for diabetes combo Qtern

AZ gets US approval for diabetes combo Qtern. Wins licensing for Onglyza/Farxiga dual-therapy after rejection by the FDA in 2015. ... Qtern is a fixed dose combination product based on the active ingredients in AZ's DPP-4 inhibitor Onglyza (saxagliptin)

More from news
Approximately 4 fully matching, plus 16 partially matching documents found.

Latest Intelligence

Transforming times at AstraZeneca

and was the pharma company with the most approvals from the US FDA with four last year, including the diabetes drug Farxiga (dapagliflozin) and Lynparza (olaparib) for ovarian cancer.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Senior Account Director, Healthcare Brand Communications, London: Excellent Package

Senior Account Manager or AD - Medical Communications: Salary TBC

Project Manager, Medical Communications, London: Excellent Salary

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Editorial Director – Medical Education – Oxford: Negotiable

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Medical Writer - (London, Brighton or Copenhagen): Competitive

Senior Medical Writer: Great salary and benefits

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Account Manager – Med Comms – London: Salary TBC

Scientific Director: Great salary and bebefits

Senior Account Manager / Account Director: Great salary and bebefits

Group Account Director, Healthcare Brand Communications, London: Excellent Package

Senior Account Manager – Med Comms – Kent: Salary TBC

Editor – Medical Education Agency – Bucks: Salary TBC

Project Manager, Medical Communications, Oxford: Excellent Salary

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Medical Writer, e-learning/ training, London: Excellent Salary

Senior Programme Executive: Salary TBC

Subscribe to our email news alerts

No results were found

PMHub

Add my company

Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation: HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...